文献速递类风湿关节炎

托法替布联合甲氨蝶呤治疗类风湿关节炎:24个月III期研究疗效与安全性

Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study.
PubMed 文献 · Arthritis Rheumatol · 2019-04-24

这项24个月、安慰剂对照的III期ORAL Scan试验评估托法替布联合甲氨蝶呤治疗对甲氨蝶呤应答不佳的活动性类风湿关节炎患者。结果显示临床疗效和影像学结构进展抑制在12至24个月维持,两种剂量疗效相似,安全性与其他托法替布研究一致。

要点

  • 托法替布5mg或10mg每日两次联合甲氨蝶呤的临床疗效从12个月维持至24个月。
  • 12个月和24个月观察到有限的结构性损伤进展。
  • 两种剂量安全性事件类型和频率相似,与既往报道一致。

核心结论

  • 对甲氨蝶呤应答不佳的活动性类风湿关节炎患者,托法替布5mg或10mg每日两次联合甲氨蝶呤的临床和影像学疗效在12至24个月维持。
  • 安全性特征与其他托法替布研究一致。

研究设计与样本

  • III期、24个月、安慰剂对照的ORAL Scan试验。
  • 患者按4:4:1:1随机接受托法替布5mg或10mg每日两次、或安慰剂(后换用托法替布5mg或10mg每日两次),背景甲氨蝶呤稳定。
  • 共治疗797例患者,539例(67.6%)完成24个月治疗。

主要发现

  • ACR20、ACR50、ACR70应答率、DAS28-ESR缓解或低疾病活动度比例、CDAI和SDAI缓解或低疾病活动度比例、Boolean缓解及HAQ-DI评分从12个月至24个月维持,两种托法替布剂量相似。
  • 12个月和24个月观察到有限的结构性损伤。
  • 两种托法替布剂量的安全性事件类型和频率相似,与既往报道一致。

关键数值与推荐

  • 临床疗效分析采用全分析集,使用观测数据或无应答者插补(无提前惩罚)。
  • 结构性进展采用线性外推法插补。

临床怎么用

  • 对甲氨蝶呤应答不佳的活动性类风湿关节炎患者,可考虑托法替布5mg或10mg每日两次联合甲氨蝶呤治疗。
  • 长期治疗(至24个月)可维持临床疗效并抑制结构性进展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). The phase III, 24-month, placebo-controlled Oral Rheumatoid Arthritis (ORAL) Scan trial was undertaken to evaluate the efficacy, including inhibition of structural progression, and safety of tofacitinib in patients with active RA and an inadequate response to methotrexate (MTX). Month 24 data from the completed study are reported here. METHODS: Patients were randomized 4:4:1:1 to receive tofacitinib 5 mg or 10 mg twice daily, or placebo, switched to tofacitinib 5 mg or 10 mg twice daily, with stable background MTX. Patients receiving placebo switched to tofacitinib at month 3 (nonresponders) or month 6 (remaining patients). Clinical efficacy, structural progression, and treatment-emergent adverse events were evaluated. Analyses were performed on the full analysis set with observed data or nonresponder imputation with no advancement penalty for clinical efficacy, and imputation by linear extrapolation for structural progression. RESULTS: Overall, 797 patients were treated; 539 (67.6%) completed 24 months of treatment. Responses according to the American College of Rheumatology criteria for 20% improvement (ACR20), ACR50, and ACR70; the proportion of patients in whom remission or low disease activity was achieved according to the 4-variable Disease Activity Score in 28 joints using the erythrocyte sedimentation rate, Clinical Disease Activity Index, or Simplified Disease Activity Index; Boolean remission; and Health Assessment Questionnaire disability index scores were maintained from month 12 to 24 and were similar between tofacitinib dosages. Limited structural damage was observed at months 12 and 24. Safety events were similar in type and frequency for both tofacitinib dosages, and were consistent with those previously reported. CONCLUSION: Our findings indicate that clinical and radiographic treatment effects are sustained in months 12-24 in patients with RA receiving tofacitinib 5 mg or 10 mg twice daily plus MTX. The safety profile is consistent with that of other tofacitinib studies.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. van der Heijde D, Strand V, Tanaka Y, et al. Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study. Arthritis Rheumatol. 2019. PMID: 30666826. doi:10.1002/art.40803

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。